Company Number: 14252657

Analysis Date: 2025-07-20 14:17 UTC

Financial Health Assessment of ASP ISOTOPES UK LTD

---

1. Financial Health Score: D

Explanation:
The company shows a minimal financial base with only £1 in cash and net assets, reflecting a nascent or early-stage entity with very limited operational activity or capitalization. This score signals caution, as the financial "vital signs" are extremely weak, resembling a patient with a critically low baseline to sustain business operations.

---

2. Key Vital Signs

Metric	Value	Interpretation
Cash in Hand	£1	Critically low liquidity; akin to a patient with negligible blood flow, indicating no operating cash.
Total Assets Less Current Liabilities	£1	Balance sheet is at a bare minimum; no buffer for liabilities or emergencies.
Shareholders’ Funds	£1	Equity capital is minimal; no retained earnings or reserves, suggesting no accumulated profits.
Number of Employees	1	Very small operational team, typical of a micro entity or start-up phase.
Account Category	Total Exemption Full	Small company filing exemption; limited disclosure, which restricts detailed financial insights.
Filing Status	Up-to-date	No overdue filings; good compliance "vital sign".
Industry Classification	Research & Development, Engineering	Indicates focus on R&D activities, which typically incur early-stage losses and require capital.

---

3. Diagnosis

ASP ISOTOPES UK LTD presents as a very early-stage, micro-sized private limited company primarily engaged in scientific research and engineering consulting. The "symptoms" of its financial position—minimal cash, negligible net assets, and no reported income statement due to small company exemption—suggest it is in the development or pre-revenue phase typical of R&D ventures.

The company’s balance sheet is essentially at its starting point, with only the initial £1 share capital recorded and no operational cash flow to speak of. This condition is analogous to a patient who has just undergone surgery and is in critical recovery with support but no independent strength yet. The absence of liabilities is a positive sign, but the lack of working capital and reserves reveals no financial stamina.

The director’s report and accounting policies indicate the company is preparing accounts on a going concern basis, but the extremely thin capital base means the company depends heavily on external funding, possibly from its ultimate parent ASP Isotopes Inc or controlling entities based in Guernsey and London.

---

4. Recommendations

To improve the financial "health" and ensure the company's long-term viability, the following actions are recommended:

• Capital Injection: Raise additional equity or secure funding lines to build cash reserves. This will provide the liquidity necessary to sustain R&D activities and cover operational costs.
• Operational Development: Progress from the research phase to development phase where possible to capitalize some costs and potentially enhance asset base and future profitability.
• Financial Monitoring: Implement robust cash flow management to avoid distress symptoms such as insolvency risk due to lack of liquidity.
• Strategic Partnerships: Seek collaborations or grants to support R&D without immediate cash outflows, reducing financial strain.
• Transparent Reporting: Consider expanding disclosures beyond exemption thresholds in future filings to attract investor confidence and demonstrate financial progress.
• Long-Term Planning: Develop a business plan forecasting revenue generation and capital requirements to guide future financial and operational decisions.

---